Trial Profile
A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vacc-4x (Primary) ; Lenalidomide; Sargramostim
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms IMID
- Sponsors Bionor Holding; Bionor Pharma
- 29 Jan 2018 According to a Bionor media release, Bionor Pharma changed its name to Bionor Holding.
- 17 Nov 2014 As per the media release, data of this trial will be submitted to a future major HIV medical conference.
- 17 Nov 2014 As per the media release, the results of this trial will be discussed with FDA and European Medical Agency (EMA)